ArticleSensors (Basel, Switzerland)2024
Blood Biomarker Detection Using Integrated Microfluidics with Optical Label-Free Biosensor.
Article in Sensors (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In this study, we developed an optofluidic chip consisting of a guided-mode resonance (GMR) sensor incorporated into a microfluidic chip to achieve simultaneous blood plasma separation and label-free albumin detection. A sedimentation chamber is integrated into the microfluidic chip to achieve plasma separation through differences in density. After a blood sample is loaded into the optofluidic chip in two stages with controlled flow rates, the blood cells are kept in the sedimentation chamber, enabling only the plasma to reach the GMR sensor for albumin detection. This GMR sensor, fabricated using plastic replica molding, achieved a bulk sensitivity of 175.66 nm/RIU. With surface-bound antibodies, the GMR sensor exhibited a limit of detection of 0.16 μg/mL for recombinant albumin in buffer solution. Overall, our findings demonstrate the potential of our integrated chip for use in clinical samples for biomarker detection in point-of-care applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.